Home › Clinical Trials › Vascular disease
COVID-19 vaccine and protecting your health ›

Vascular disease

Viewing Page 2 of 20 | Showing results 11 - 20 of 194

(CIRB) Molecular Analysis for Therapy Choice (MATCH)

Daniela Bota
Open

(CIRB) Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Daniela Bota
Open

(CIRB) Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Krishnansu Tewari
Open

(CIRB) Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Parima Daroui
Open

(CIRB) Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Rita Mehta
Open

(CIRB) Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma

Xiao-Tang Kong
Open

(CIRB) Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Krishnansu Tewari
Open

(CIRB) Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Elizabeth A Brem
Open

(Quorum) A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment

Ritesh Parajuli
Open

(WIRB) A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Krishnansu Tewari
Open